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Abstract
Direct haemoperfusion with polymyxin B-immobilized fibre (PMX-F)
is a promising treatment for Gram-negative sepsis in critically ill
patients. Indeed, it has been used routinely in Japan for a decade.
Recent evidence presented in this journal suggests that PMX-F
can have a positive impact on outcome in patients with sepsis,
although other reports in the literature have presented confusing or
even conflicting results. This commentary considers whether the
available evidence allows us to establish an appropriate role for
PMX-F treatment in sepsis and what further work is needed.
Introduction
A few years ago a new device for extracorporeal removal of
circulating endotoxin entered the market (Toraymixin; Toray
Industries, Osaka, Japan). The device uses polystyrene fibres
coated with polymyxin B (which adheres via covalent bonds)
that are incorporated in a sorbent column; this column is then
used in an extracorporeal haemoperfusion circuit. The device
is intended to be used as an adjuvant therapy, adsorbing
endotoxin and other products and possibly improving the
altered immunohomeostasis characteristic of Gram-negative
sepsis in critically ill patients. A report by Kushi and
coworkers [1] presents important evidence for a positive
impact of the device on outcome in septic patients.
Several other reports have been published, but these have
often presented confusing or conflicting results [2-5].
Nevertheless, polymyxin B-immobilized fibre (PMX-F) has been
used routinely in Japan since 1995, and more than 50,000
septic patients have been treated. So, is it now possible to
determine a clear role of PMX-F treatment in the therapy of
sepsis? What work has been done thus far, and what must be
added to the research agenda if we are to complete our
evaluation?
Safety
The proposal that the toxic molecule polymyxin B, bound to
fibres, be placed in contact with circulating blood promptly
led to concerns about safety and biocompatibility. This is
logical because use of haemoperfusion devices has been
reported to result in thrombocytopenia and leucocytopenia.
There was additional concern that polymyxin B could be
released into the circulation. However, these fears were laid
to rest when data indicating excellent biocompatibility were
reported [6-8]. Nevertheless, PMX-F treatment is contra-
indicated in patients in whom the use of heparin would cause
uncontrolled bleeding or in whom adequate anticoagulation
cannot safely be achieved, such as those with haemophilia or
with known hypersensitivity to heparin or PMX-F.
Performance
The PMX-F cartridge has been studied in vitro and in animals
and humans. Several reports demonstrated efficient removal
of entotoxin from blood passing through the sorbent bed.
Also, flow distribution in the cartridge has been shown to be
homogeneous and to utilize all available surface for
adsorption [9].
Indications
Sepsis and septic shock are common among critically ill
patients. Also, a systemic inflammatory response syndrome
may present as a primary cause of multiple organ failure.
In this setting continuous renal replacement therapy has been
used to achieve adequate blood purification. Proposed use of
these techniques for additional removal of proinflammatory
mediators and endotoxin products has attracted increasing
interest. However, only small quantities of proinflammatory
substances have been identified in the filtrate during
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continuous haemodiafiltration. There are various ways to
increase the extracorporeal removal of proinflammatory
mediators. One is to perform haemofiltration with high
volumes (6 l/hour for 4–8 hours/day) using standard haemo-
filtration membranes. Another is to employ membranes with
greater permeability and utilize plasmafiltration techniques. A
third option is to use sorbent devices in haemoperfusion
techniques. PMX-F treatment is indicated for use in patients
with sepsis or septic shock caused by Gram-negative
bacteria. Because of the high affinity of PMX-F for endotoxin,
the rationale underlying extracorporeal therapy would be to
remove circulating endotoxin by adsorption, thus preventing
progression of the biological cascade of sepsis [10,11].
Patient selection
The primary goal of most studies was to test the ability of the
cartridge to remove components of Gram-negative bacteria in
the hope of improving outcome, but patient selection for the
trials has been very difficult. In fact, in those studies in which
Gram-negative sepsis was presumed, such infection was
confirmed only occasionally. This has made the majority of
studies either nonsignificant or at least underpowered,
limiting the validity of the evidence for use of PMX-F
treatment in Gram-negative sepsis. Statistically significant
results and sufficient statistical power require the recruitment
and study of greater numbers of patients with true Gram-
negative infection. Unfortunately, it is difficult to determine at
the time of enrolment whether a patient really has Gram-
negative infection, and one must often wait at least 48 hours
for culture results. Moreover, no organism is cultured in
approximately 30% of patients with overt clinical sepsis. A
number of studies might have failed to yield statistically
significant findings because of nonspecific patient selection.
End-points
The definition of end-points for studies of PMX-F treatment is
generally difficult and problematic. If the therapy is
considered an adjuvant tool to prevent progression down the
slippery slope of multiple organ syndrome resulting from a
biochemical cascade of mediators, then we can compare
PMX-F treatment with high-dose steroids. Both therapies may
be important, especially at the beginning of the syndrome, but
they do not have a causative approach or remove the origin of
sepsis. In this setting, physiological end-points such as
reduction in vasopressor support, improvement in
haemodynamics and reduction in severity scores have been
used more than solid outcome measures. Nevertheless, some
studies have reported improvement in organ damage, and
even improvement in survival.
The biological versus the clinical clock
Despite the biological rationale and the apparently excellent
performance of the cartridge, an intriguing issue arises when
definitive testing of this technology is performed. Over the
time course of sepsis, we can distinguish between a
biological and a clinical clock. The first starts when infection
begins and fragments of Gram-negative bacteria invade the
host. At this point, immediate intervention with a treatment
designed to remove the substance initiating sepsis would
probably result in blockade of the humoral response and the
subsequent biochemical cascade. In contrast, the clinical
clock starts only after the first signs and symptoms appear
and patients exhibit the initial sepsis syndrome. At this point
humoral and tissue derangement has already begun and
organ damage may occur momentarily if not yet present. In
these circumstances, intervention with extracorporeal therapy
can only result in possible organ protection from further
insults; it cannot achieve effective blockade of the syndrome.
What’s next?
It would be reasonable to follow at least some of the following
steps. The aim should be to synchronize the biological and
the clinical (diagnostic) clocks. To achieve this we must work
on possible early markers of Gram-negative sepsis that could
be used to identify patients at risk and make the case for early
application of PMX-F therapy. Gene polymorphisms for
expression of different molecules could be one avenue to
explore. Furthermore, we must analyze the types of sepsis,
some of which are almost inevitably sustained by Gram-
negative bacteria, as in the case of peritonitis. In such cases
it may be logical to apply the therapy based on the assumed
presence of infection. The latter approach has been
undertaken by a group of investigators coordinated by two
centers, including ours, in the EUPHAS (Early Use of
Polymixin-B Hemoperfusion in Abdominal Sepsis) study. The
study was begun a year ago and will complete enrolment
during the next 12 months. This multicentre randomized
controlled study should provide a definitive answer regarding
the efficacy of PMX-F treatment, because it has been
designed with an adequate sample size and with strict
indications for specific clinical conditions.
Conclusion
There is a good biological rationale for the PMX-F device, and
it represents a potential therapy for patients with early Gram-
negative sepsis. Some technical and clinical issues have
been resolved, but more work must be done. The EUPHAS
study should significantly enhance our understanding of the
real efficacy of this therapy.
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